CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder’s Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock. CEL-SCI expects the split to be …
ABC61mon
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an …
AOL3y
It is progressing from a clinical-stage biotech stock to a commercial-stage company with life-saving treatments in the emerging field of cancer immuno-therapy. But data show Kite’s most advanced candidate, axi-cel/ KTE-C19, is a …
CEL-SCI Corporation (CVM) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 142.43 P/E and the sector P/E is 17.21. If the $0.08 price target is reached, the company will be worth $1.21 million less. CEL-SCI …
That's a total unknown that simply can't be answered right now. Kite is arguably the better stock to own at the moment because of Axi-Cel's near-term commercial prospects. Agenus, after all, is still three to four years away from bringing …
Cellcom Israel Ltd. engages in the provision of cellular communications services. It operates through two segments: Cellcom and Netvision. The Cellcom segment includes Cellcom Israel Ltd. and its subsidiaries. The Netvision segment …
Kite, for its part, is expected to follow suit and price Axi-Cel in the range of $200,000 to $300,000 per ... Does this mean that Juno's stock is a compelling buy? Unfortunately, the answer to this question is a "maybe" at best. Novartis and …
Taking a look into the performance of CVM stock, investor will come to know that the weekly performance for this stock is valued at -20.56%, resulting in a performance for the month at -22.73%. Another critical number in evaluating a stock is …